Part of MSC's ability to encourage CLL cell survival is independent of the NF-κB pathway, with transforming growth factor β1 (TGFβ1) and stromal cell derived factor 1 (SDF1) driving CLL cell survival (45). Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.